ScandiBio Therapeutics

info@scandibio.com
  • About Us
    • Our Science
    • Scientific rationale
    • The Team
  • Clinical Studies
    • Phase I/II: SERINE
    • Phase I: METABOLIC COFACTORS
    • Phase II: NAFLD
    • Phase II: AD/PD
    • Phase II: COVID-19
    • Phase III: COVID-19
  • Publications
  • News
  • Contact

Monthly Archives: May 2020

ScandiBio Therapeutics   →  2020   →  May
19
May
Date May 19, 2020
Categories News

A review article has been published about the use of AI-based systems biology for drug development to treat neurodegenerative diseases

A review paper has been published in the journal Drug Discovery Today discussing the use of systems biology approaches for studyin...
Read More
Author SCANDIBIO
15
May
Date May 15, 2020
Categories News

A phase II study in COVID-19 patients using CMCS been initiated

ScandiBio Therapeutics has initiated a Phase II study in patients with COVID-19 using Combined Metabolic Cofactors Supplementation...
Read More
Author SCANDIBIO

Categories

  • News 16

Recent Posts

  • Metabolic Activators Therapy Improve Liver Fat in NAFLD PatientsOctober 25, 2021
  • Phase 2 human clinical trial shows that metabolic activators improve cognitive function in Parkinson’s disease patientsAugust 5, 2021
  • Phase 2 human clinical trial shows that metabolic activators improve cognitive function in Alzheimer’s disease patientsJuly 20, 2021
  • The results of a phase II and III clinical trials about the treatment of COVID-19 patients with CMAs have been published at Advanced ScienceJune 29, 2021
  • Phase 3 human clinical trial shows that metabolic activators accelerates recovery in COVID-19 patientsFebruary 24, 2021

Archives

  • October 2021
  • August 2021
  • July 2021
  • June 2021
  • February 2021
  • October 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
Copyright © 2020 ScandiBio Therapeutics. All rights reserved.